SpringWorks Therapeutics (SWTX) Guggenheim’s Inaugural Healthcare Innovation Conference summary

Commercial performance and market opportunity

• Ogsiveo has outperformed initial expectations, with the market size for desmoid tumors in the U.S. now estimated at over 10,000 patients, significantly higher than previously thought.

• The drug is now considered the systemic standard of care, with peak U.S. sales potential projected well above $1 billion.

• Introduction of new blister pack formulations in Q3 led to a temporary slowdown in prescription renewals, but growth resumed with record months in August and September.

• Blister packs are expected to improve patient adherence and refill consistency, with the migration to be completed by year-end.

• Over 400 prescribers have used Ogsiveo, and more than 60% expect to increase usage next year.

Physician adoption and patient access

• Ogsiveo is increasingly used as first-line therapy, with survey data indicating strong physician preference and repeat prescribing.

• Attitudes among physicians are shifting toward earlier intervention based on symptoms, aided by a label that includes pain reduction.

• Commercial infrastructure is largely right-sized, but expansion is considered to reach more community physicians and reduce unnecessary surgeries.

• Efforts focus on reducing watchful waiting and increasing early access to therapy.

Regulatory and geographic expansion

• European launch is anticipated next year, starting in Germany, leveraging strong relationships with key opinion leaders and over 250 patients already on compassionate use.

• Commercial team hiring is underway in Europe, with confidence in the ability to access patients across key territories.